CSIMarket Company Name, Ticker, Competitors, else..
 
Ataibeckley Inc   (NASDAQ: ATAI)
 
Price: $7.3350 $-0.01 -0.068%
Day's High: $7.349999904632568 Week Perf: -0.07 %
Day's Low: $ 7.32 30 Day Perf: 2.16 %
Volume (M): 991,682 52 Wk High: $ 7.45
Volume (M$): $ 0 52 Wk Avg: $4.77
Open: $7.33 52 Wk Low: $3.27



 Market Capitalization (Millions $) 2,646
 Shares Outstanding (Millions) 361
 Employees 202
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -668
 Cash Flow (TTM) (Millions $) -19
 Capital Exp. (TTM) (Millions $) 15

Business Description


Atai Life Sciences N.V. is a global biotech company that specializes in developing transformative therapies for mental health disorders. The company focuses on discovering and developing innovative treatments for conditions such as depression, anxiety, addiction, and other related disorders. They strive to address the unmet needs in mental health by utilizing cutting-edge research, technology, and strategic partnerships. Atai Life Sciences aims to improve the way mental health disorders are diagnosed, treated, and understood to ultimately enhance the quality of life for individuals suffering from these conditions.


   Company Address: c/o atai Life Sciences US, Inc. New York 10119 NY
   Company Phone Number: 282-0507   Stock Exchange / Ticker: NASDAQ ATAI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ANRO        1.34% 
CMPS   -4.41%    
ENVB        2.93% 
INDV        0.49% 
IXHL   -9.07%    
XENE   -0.82%    
• View Complete Report
   



Clinical Study

Atai Life Sciences Advancing Psychiatric Treatments Amid Fiscal Trials and Industry Competition,

Published Thu, Mar 13 2025 4:09 AM UTC

Atai Life Sciences: Navigating Financial Challenges Amid Promising Clinical Trials for Treatment-Resistant DepressionAtai Life Sciences, a leading innovator in the biotechnology and mental health sectors, has recently achieved a significant milestone in its clinical research. The company announced the completion of participant enrollment for its Phase 2b clinical trial eval...
Shares

Atai Life Sciences Secures $63 Million: A Game-Changer in Mental Health Treatment Funding

Published Thu, Feb 13 2025 3:47 AM UTC

Atai Life Sciences: Pioneering the Future of Mental Health TreatmentIn a momentous move poised to redefine the landscape of mental health treatment, Atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company, has initiated a major underwritten offering of common shares. The company announced on February 12, 2025, that it priced 26,190,477 shares at a subst...
Stock Market Announcement

Atai Life Sciences Secures $63 Million in Public Offering as It Advances Innovative Mental Health Treatments

Published Thu, Feb 20 2025 12:00 PM UTC

In a significant move to bolster its operations, Atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company dedicated to revolutionizing mental health disorder treatments, announced the successful closing of its public offering on February 14, 2025. The company sold a total of 26,190,477 common shares during this offering, which has drawn considerable inve...
Clinical Study

atai Life Sciences Advances the Treatment of Major Depressive Disorder with ELE-101 Trial Promising Results from Phas...

Published Thu, Jun 20 2024 11:01 AM UTC

In recent years, mental health disorders have emerged as one of the most significant and challenging global healthcare concerns. Major Depressive Disorder (MDD) affects millions of individuals worldwide, causing debilitating symptoms and diminishing their quality of life. Recognizing the pressing need for innovative solutions, atai Life Sciences, a renowned clinical-stage bi...
Clinical Study

Groundbreaking Study Commences: atai Life Sciences Initiates Dosing of BPL-003 in Phase 2a Trial for Treatment-Resistant Depression

Published Wed, Apr 24 2024 11:01 AM UTC

atai Life Sciences, a renowned clinical-stage biopharmaceutical company focused on revolutionizing the treatment of mental health disorders, has successfully administered the first dose of BPL-003 (intranasal 5-MeO-DMT) to a patient in the second phase of Beckley Psytech s Phase 2a clinical trial. This groundbreaking study aims to explore the potential benefits of BPL-003 as...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 591.58
Price to Sales (Expected) -
Price to Book 15
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.43
Working Capital Ratio 4.97
Leverage Ratio (MRQ) 1.62
Total Debt to Equity 0.13
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.91 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) -
Cash 0.47 $
Book Value 0.49 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 22,144
Net Income per Employee (TTM) -3,308,347
Receivable Turnover Ratio (TTM) 13.83
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.02

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -2590.43 %
Net Margin (MRQ) -1910.09 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Ataibeckley Inc's Segments
Research and development services revenue Reportable Aggregation before Other Segment    37.44 % of total Revenue
Research and development services revenue    118.49 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.